Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
10 April 2025 - Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Non-Executive Director Peter Presland has today purchased 3,398,553 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 0.44p per share.
Following this transaction, Peter Presland is beneficially interested in a total of 3,398,553 Ordinary Shares, representing approximately 0.17% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name | Peter Presland | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/status | Director/PDMR | ||||||
| b) | Initial notification/ Amendment | Initial notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | Oxford BioDynamics Plc | ||||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572 | ||||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | ||||||
| c) | Price(s) and volume(s) |
| ||||||
| d) | Aggregated information - Aggregated volume - Price
| n/a
| ||||||
| e) | Date of the transaction | 10 April 2025 | ||||||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||||||
-Ends-
For further details please contact:
| Oxford BioDynamics Plc Iain Ross, Executive Chairman Paul Stockdale, CFO
| +44 (0)1865 518910 |
| Shore Capital - Nominated Adviser and Broker Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy
| +44 (0)20 7408 4090 |
| WG Partners - Joint Broker David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby
| +44 (0)20 3705 9330 |
| OAK Securities - Joint Broker Jerry Keen / Henry Clarke / Damion Carruel
| +44 (0)20 3973 3678 |
| Camarco - Financial PR Marc Cohen / Tilly Butcher / Fergus Young
| +44 (0)20 3757 4980 OBDFinancial@camarco.co.uk |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.